Fact: Large-scale cardiovascular trials have found no evidence that GLP-1 receptor agonists increase the risk of blood clots
Key Considerations for Entering the GLP-1 Market Large pharmaceutical companies have already set the global standard by demonstrating how scientific innovation, robust partnerships, and reliable delivery systems can drive both patient impact and market leadership
This means the exact time you take your injection matters less than taking it on schedule
Implications for employers: This adds to the evidence that GLP-1 drugs benefit members at high risk of limb complications and premature death, though this study found no reduction in heart attack or stroke
Use an alcohol swab to clean the rubber stopper before inserting the needle
Pozzi C, Marai P, Ponti R, Dell'Oro C, Sala C, Zedda S, Locatelli F